Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Trader J's Inner Circle -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (7421)	2/3/1999 1:32:00 AM
From: snerd	Read Replies (1) \| Respond to of 56532

OT... All... Photos; Please PM me for e-mail address to send your photos. Do NOT use the address in my profile, as that is just a junk mail address. I check it maybe once a week just to delete them. I fished two pics out of there tonight. ; ) Added two more tonight, so have a look see. shop-southwest-ok.com Snerd PS: That Buddy Smellgood! LOL!! ; - D

To: Mike McFarland who wrote (7421)	2/3/1999 9:19:00 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 56532

re Incyte...earnings For the quarter ended December 31, 1998, Incyte reported revenues of $36.6 million resulting in net income of $1.5 million or $0.05 per diluted share... The net income for the quarter and year ended December 31, 1998 were impacted by the ramp up in expenses related to the genomic sequencing and single nucleotide polymorphism (SNP) discovery programs previously attributed to the Incyte Genetics business unit. Excluding the impact of this business unit, net income would have been $6.9 million or diluted earnings per share of $0.23 for the quarter ended December 31, 1998. --and it looks like they are not going to do the tracking stock...Incyte Genetics, so perhaps the earnings estimates were already excluding that? biz.yahoo.com So I am pretty sure that earnings were forecast as .77/.21 and turned out .54/.05, but we have to consider that they may actually have been in line based in whether the Incyte Genetics unit was supposed to be in there.

To: Mike McFarland who wrote (7421)	2/6/1999 9:30:00 AM
From: Mike McFarland	Respond to of 56532

Followup... I'm not quite ready to start a genomics thread...but I did start a gene therapy thread just now. Subject 25613 Like most of the genomics stocks (besides affx and incy) the gene therapy stocks are generally not very tradable. I've had some success trading them, but it was just luck. Still, a very interesting area of biotech, and worth a look, at least for investment ops. As far as trading, you may remember my most recent trade was a profitable position trade on tgen...I am looking to re-enter that one...on a dip below $2. all for now.